(Q34767213)

4 August 2017

1 reference

title

The cancer biomarker problem (English)

1 reference

4 August 2017

0 references

Charles L Sawyers

1

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

4 August 2017

1 reference

4 August 2017

volume

452

1 reference

4 August 2017

issue

7187

1 reference

4 August 2017

page(s)

548-552

1 reference

Microarrays: retracing steps

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

Letting the genome out of the bottle--will we get our wish?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

7 January 2021

Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

7 January 2021

Biomarkers in drug development: friend or foe? A personal reflection gained working within oncology.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

7 January 2021

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

7 January 2021

Epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

7 January 2021

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

7 January 2021

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

7 January 2021

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

7 January 2021

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

7 January 2021

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

7 January 2021

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

7 January 2021

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

7 January 2021

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

7 January 2021

Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

7 January 2021

Isolation of rare circulating tumour cells in cancer patients by microchip technology

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

7 January 2021

Genomic signatures to guide the use of chemotherapeutics.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

7 January 2021

Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

7 January 2021

High-throughput oncogene mutation profiling in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

7 January 2021

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

7 January 2021

Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

7 January 2021

Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

7 January 2021

Oncogenic pathway signatures in human cancers as a guide to targeted therapies

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

7 January 2021

Detection and quantification of mutations in the plasma of patients with colorectal tumors

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

7 January 2021

Autoantibody signatures in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06913

7 January 2021

Identifiers

DOI

10.1038/NATURE06913

1 reference

Dimensions Publication ID

4 August 2017

1030001320

0 references

1 reference